Proactive Investors - Run By Investors For Investors

Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon

The company plans to begin recruitment for its upcoming dose expansion cohort immediately.
Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon
Kazia’s shares last traded at 44 cents each

Kazia Therapeautics Limited (ASX:KZA) has a new substantial holder in The Bank of New York Mellon Corporation (NYSE:BK) which recently staked a 27.09% interest.

The world’s largest custodian bank now holds a total of 16,840,686 securities in the Australian oncology-focused biotech company.



Kazia Therapeutics chief executive officer James Garner said the superior results from the ongoing study of GDC-0084 in newly-diagnosed glioblastoma patients was an important milestone for the company.

He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.

READ: Kazia Therapeautics’ ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

Garner continued: “One of the exciting things about our drug GDC-0084 is that its designed to cross the blood-brain barrier.

“We are focusing on newly-diagnosed patients in earlier stages of the disease and we think we can offer a much bigger benefit there.”

The company confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study earlier this week.

View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

Related Articles

Medical scanner
February 09 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use